+91-8668442535

Gout Therapeutics Market By Drug Class (Non-Steroidal Anti-Inflammatory Drugs (NSAIDS), Colchicine, Corticosteroids, Uric Acid Lowering Agents) - Growth, Future Prospects, And Competitive Analysis, 2017 - 2025

Gout is a complex form of inflammatory arthritis characterized by recurrent attacks of severe pain and swollen joints. The gout therapeutics market is rapidly growing due to factors such as the growing incidence of gout, significant unmet needs, growing treatment awareness, and promising pipeline molecules. The incidence of gout varies widely around the globe, with developed countries generally having a higher prevalence than developing countries due to genetic, dietary, and environmental factors. Favorable reimbursement policies by government agencies and private organizations in developed countries, the growing number of obese people, and rising treatment compliance are other factors that are fueling the market growth of gout therapeutics.

The report titled "Gout Therapeutics Market: Growth, Future Prospects, and Competitive Analysis, 2017–2025" offers strategic insights into the overall gout therapeutics market, along with the market size and estimates for the duration of 2015–2025. The research study covers an in-depth analysis of market segments based on drug class (non-steroidal anti-inflammatory drugs, colchicine, corticosteroids, and uric acid-lowering agents) and different geographical regions.

Geographically, the global gout therapeutics market is studied for the following regional markets:

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of LATAM
  • Middle East and Africa
    • GCC
    • the remainder of MEA

The market size and forecast for these regional and country-level markets are presented in this study for the period 2015–2025. Market growth rates for the forecast period 2017–2025 are also included in this report, considering 2016 as the base year.

Along with quantitative information, qualitative information sets and assessment tools are provided in this study for a better analysis of the overall market scenario and future prospects. Information such as drivers, challenges, and opportunities assists the readers in understanding the ongoing trends in the global gout therapeutics market. Pipeline analysis of gout therapeutics and the global epidemiology of gout have been included in the study. Tools such as key player market positioning and appealing investment propositions provide readers with insights into the competitive landscape of the global gout therapeutics market. This report concludes with a company profiles section that highlights major information about the key players engaged in the global gout therapeutics market. In-depth competitive environment analysis and historical year (2015) market size data are also provided in the report.

Thus, the research study provides a holistic view of the global gout therapeutics market, offering market size and estimates for the period from 2015 to 2025, keeping in mind the above-mentioned factors.

Based on drug classes, the global gout therapeutics market is segmented as follows:

  • Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
  • Colchicine
  • Corticosteroids
  • Uric acid-lowering agents

Gout is a complicated type of arthritis characterized by sudden, severe attacks of joint pain and tenderness. The incidence of gout has increased to a great extent in the past two decades. According to the U.S. Centers for Disease Control and Prevention (CDC), gout affects approximately 4 percent of Americans. Therapeutics not only treat gout symptoms but also prevent future flares and reduce the risk of complications. Colchicine, corticosteroids, and NSAIDs such as ibuprofen, naproxen, celecoxib, indomethacin, etc., are recommended in the treatment of acute gout attacks. Currently, NSAIDs are dominating the gout therapeutics market due to their wide availability, lower price, and ability to reduce gout pain and inflammation.

Combination therapy of uric acid lowering agents is widely administered, and it is estimated that it will show significant market growth during the forecast period due to its faster onset of action and minimal adverse effects. Diallo (lesinurad and allopurinol), approved in 2017, is touted as a promising drug for gout treatment, and Ironwood expects to exceed total annual U.S. peak sales of $300 million. The presence of ideal pipeline molecules, such as halogenate, bucillamine, levotofisopam, ulodesine, verinurad, etc., would assist in achieving significant market growth during the forecast period of 2017–2025. Due to target specificity and efficacy, demand for biologics is expected to increase in the market. At present, approved biologics such as canakinumab and kystexant are driving the growth of the gout therapeutics market globally.

For the purpose of this study, the global gout therapeutics market is categorized into three segments:

  • North America
  • Europe
  • Asia Pacific
  • Latin America (LATAM)
  • Middle East and Africa (MEA)

The prevalence and incidence of gout vary widely around the globe, with developed countries generally having a higher prevalence than developing countries due to genetic, dietary, and environmental factors. However, the highest prevalence worldwide is reported in the Taiwanese, with some estimates of more than 10%. It is known that, in the base year 2016, North America dominated the gout therapeutics market. The United States was the largest revenue contributor due to the upsurge in funding by government agencies and private organizations in the healthcare system, the higher cost of therapeutics, and a large number of target populations with high treatment awareness.

According to the Centers for Disease Control and Prevention (CDC), more than 4 percent of the population is affected by gout in the United States. The expected launch of pipeline molecules, such as arhalofenate, bucillamine, levotofisopam, ulodesine, verinurad, etc., is expected to assist gout therapeutics market growth in North America. On the other hand, Asia Pacific is estimated to show the fastest market growth over the forecast years due to the rising number of affected populations, growing investment by key players with local manufacturers in the region, and rapidly improving healthcare infrastructure. Furthermore, changing lifestyle patterns and growth rates of smoking and alcohol consumption will boost the gout therapeutics market over the forecast period of 2017–2025.

Frequently Asked Questions:

The market for Gout Therapeutics Market is expected to reach USD XX Mn By 2025.

The Gout Therapeutics Market is expected to see significant CAGR growth over the coming years, at 15.6%.

The report is forecasted from 2017-2025.

The base year of this report is 2016.

Takeda Pharmaceutical Company Ltd., Savient Pharmaceuticals, Inc., Horizon Pharma Plc., Cymabay Therapeutics, Inc., BioCryst Pharmaceuticals, Inc. are some of the major players in the global market.

Choose License Type
Trusted By
Godaddy
Published Date:  Nov 2017
Category:  Pharmaceuticals
Report ID:   58808
Report Format:   PDF
Pages:   120
Rating:    4.8 (60)
Delivery Time: 24 Hours to 48 Hours   
Connect With Us
+91-8668442535
24/7 Research Support